Advancements in biomarker targeting
KRAS is the most common driver mutation in NSCLC. KRAS G12C represents nearly half (44%) of all KRAS mutations in NSCLC.
Normal KRAS protein cycles between an active and inactive form, regulating normal cell proliferation, differentiation, and survival. The KRAS G12C mutation favors the active form of the KRAS mutant protein, supporting cancer cell growth and survival.
Based on the rapid developments in biomarkers over the past few years, how quickly would you move to incorporate the testing and treatment of a new actionable biomarker?
How would you manage current patients who were previously biomarker negative, or who had progressed on treatment with another targeted agent? Would you re-test them looking for the new biomarker?